Quick Takeaways
- EVENTIDE ASSET MANAGEMENT, LLC filed SCHEDULE 13G/A for Celldex Therapeutics, Inc. Common Stock, par value $0.001 (CLDX).
- Disclosed ownership: 2%.
- Date of event: 30 Jun 2025.
EVENTIDE ASSET MANAGEMENT, LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Celldex Therapeutics, Inc. Common Stock, par value $0.001 (CLDX)
- Filing Manager
- EVENTIDE ASSET MANAGEMENT, LLC
- Reporting Manager
- Eventide Asset Management, LLC
- Symbol
- CLDX
- Shares outstanding
- 67,809,300 shares
- Disclosed Ownership
- 1,356,186 shares
- Ownership
- 2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 14:59:36 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"EVENTIDE ASSET MANAGEMENT, LLC disclosed 2% ownership in Celldex Therapeutics, Inc. Common Stock, par value $0.001 (CLDX) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 14:59.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Eventide Asset Management, LLC | 2% | 1,356,186 | 1,356,186 | 0 | /s/ Peter J. Luiso | Peter J. Luiso, General Counsel | |
| Finny Kuruvilla, M.D. Ph. D. | 2% | 1,356,186 | 0 | 1,356,186 | /s/ Finny Kuruvilla, M.D., Ph. D. | Finny Kuruvilla, M.D., Ph. D. | |
| Robin C. John | 2% | 1,356,186 | 0 | 1,356,186 | /s/ Robin C. John | Robin C. John |